EN PL

News

MHRA: Three new publications have been added to the Labels, patient information leaflets and packaging for medicines section

23.10.2009
Two BROMI (Better regulation of medicines initiative) audit reports and Code of Practice for pack design for over-the-counter medicines have been added to the Labels, patient information leaflets ...

FDA: Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects

23.10.2009
This guidance provides an overview of the responsibilities of a person who conducts a clinical investigation of a drug, biological product, or medical device (an investigator as defined in 21 CFR ...

EMEA: ICH Topic E7 Studies in Support of Special Populations

21.10.2009
ICH Topic E7 Studies in Support of Special Populations: Geriatrics - Questions and answers ...

European Commission: Assessment of the functioning of the \"Clinical Trials Directive” 2001/20/EC - Public consultation paper

21.10.2009
Requirements for the conduct of clinical trials in the EU are provided for in the “Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the ...

MHRA: Introduction of the Traditional Herbal Registration certification mark

21.10.2009
The Traditional Herbal Registration (THR) certification mark is a type of trade mark, indicating that a herbal medicine has been registered with the MHRA under the Traditional Herbal Registration ...

FDA: Labeling for Human Prescription Drug and Biological Products — Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information

21.10.2009
This guidance is intended to provide applicants and review staff with a definition of established pharmacologic class and to help them identify the most appropriate word (term) or phrase that ...

FDA: Helicobacter pylori-Associated Duodenal Ulcer Disease in Adults: Developing Drugs for Treatment

02.10.2009
The purpose of this guidance is to assist sponsors in clinical drug development for the treatment of adults with duodenal ulcers caused by Helicobacter pylori (H. pylori) for the reduction of ...

FDA: Format and Content of Proposed Risk Evaluation and Mitigation Strategies (REMS), REMS Assessments, and Proposed REMS Modifications

02.10.2009
This guidance applies to certain drug and biological products submitted for approval or approved under sections 505(b) or 505(j) of the Federal Food, Drug, and Cosmetic Act (FDCA), or section 351 ...

MHRA: Detailed Description of the Pharmacovigilance System for Parallel Imported Products

30.09.2009
There are a small number of instances where a parallel importing company is required to take on responsibility for pharmacovigilance. Examples of such instances include: when the UK reference ...

European Commission: Substances considered as not falling within the scope of Council Regulation (EC) No. 470/2009 (Revision 17 – September 2009)

30.09.2009
Substances considered as not falling within the scope of Council Regulation (EC) No. 470/2009 (Revision 17 – September 2009) ...